2. Search Result
Search Result
Results for "

serum+triglyceride

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

4

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-W012946
    2-Furoic acid

    Pyromucic acid

    		 Environmental Pollutants Endogenous Metabolite Acyltransferase ATP Citrate Lyase Metabolic Disease
    2-Furoic acid (Furan-2-carboxylic acid) is an organic compound produced through furfural oxidation . 2-Furoic acid exhibits hypolipidemic effet, lowers both serum cholesterol and serum triglyceride levels in rats .
    2-Furoic acid
  • HY-N0241
    Rhodionin

    		Cholinesterase (ChE) Lipase Bacterial Cytochrome P450 Infection Metabolic Disease
    Rhodionin is an orally active, multifunctional antivirulence and cytoprotective agent that targets and inhibits Lipase, sortase A (SrtA), CYP2D6 (IC50=0.761 μM), AChE (IC50=2.43-57.5 μM), and DPPH free radicals (IC50=19.49 μM). Rhodionin is isolable from the roots of Rhodiola crenulata. Rhodionin reduces postprandial serum triglyceride levels in mice by inhibiting lipase activity. Rhodionin also binds directly to SrtA to inhibit its transpeptidase activity, thereby reducing the fibrinogen adhesion and surface protein A levels of MRSA, effectively inhibiting biofilm formation and protecting against MRSA-induced cell damage. Rhodionin improves the survival rate of infected mice without affecting MRSA growth, and finds wide application in studies related to hyperlipidemia, exogenous obesity, and pneumonia induced by methicillin-resistant Staphylococcus aureus (MRSA) .
    Rhodionin
  • HY-19852
    KRP-105

    		PPAR Metabolic Disease
    KRP-105 is a potent, highly selective, and orally effective PPAR alpha (EC50 = 8 nM) agonist. KRP-105 can significantly reduce serum triglyceride, total cholesterol, and non high density lipoprotein cholesterol levels. KRP-105 can be used for research on metabolic diseases such as dyslipidemia .
    KRP-105
  • HY-W012946S
    2-Furoic acid-d3

    		Acyltransferase ATP Citrate Lyase Endogenous Metabolite Metabolic Disease
    2-Furoic acid-d3 is the deuterium labeled 2-Furoic acid . 2-Furoic acid (Furan-2-carboxylic acid) is an organic compound produced through furfural oxidation . 2-Furoic acid exhibits hypolipidemic effet, lowers both serum cholesterol and serum triglyceride levels in rats .
    2-Furoic acid-d3
  • HY-118364
    AGN 190727

    		RAR/RXR Metabolic Disease
    AGN 190727 is a structural isomer of AGN 190121 and has no activating effect on RAR/RXR. AGN 190121 is a RAR-specific agonist that causes a dose-dependent increase in serum triglycerides, leading to hypertriglyceridemia.
    AGN 190727
  • HY-N11551
    Salvifaricin

    		Others Others Metabolic Disease
    Salvifaricin is an orally active diterpenoid compound that can be isolated from Salvia leucantha Cav. and Salvia hispanica L.. Salvifaricin significantly reduces fasting blood glucose and serum triglyceride (TG) levels, and has anti-diabetic effect .
    Salvifaricin
  • HY-19418
    KRP-101

    		PPAR Others
    KRP-101 is a compound that regulates the expression of genes related to lipid metabolism. It is a PPARα agonist that can highly sensitively regulate the expression of genes such as apolipoprotein A-IV, which may be related to lowering serum triglycerides and increasing HDL.
    KRP-101
  • HY-W012946R
    2-Furoic acid (Standard)

    Pyromucic acid (Standard)

    		 Reference Standards ATP Citrate Lyase Acyltransferase Endogenous Metabolite Metabolic Disease
    2-Furoic acid (Standard) is the analytical standard of 2-Furoic acid. This product is intended for research and analytical applications. 2-Furoic acid (Furan-2-carboxylic acid) is an organic compound produced through furfural oxidation . 2-Furoic acid exhibits hypolipidemic effet, lowers both serum cholesterol and serum triglyceride levels in rats .
    2-Furoic acid (Standard)
  • HY-165095
    1,2-Dipalmitoleoyl-3-palmitoyl-rac-glycerol

    1,2-Palmitolein-3-palmitin; TG(16:1/16:1/16:0)

    		 Others Others
    1,2-Dipalmitoleoyl-3-palmitoyl-rac-glycerol (1,2-Palmitolein-3-palmitin) is a triglyceride used for serum lipidomics analysis by liquid chromatography-mass spectrometry. This method can effectively separate and detect lipids in positive and negative ionization modes and has certain performance in the identification and characterization of serum triglycerides.
    1,2-Dipalmitoleoyl-3-palmitoyl-rac-glycerol
  • HY-19227
    BM 170249

    		PPAR Cardiovascular Disease
    BM 170249 is a peroxisome proliferator, particularly in the perivenous region of the central acini in the liver. BM 170249 significantly reduces serum triglyceride and cholesterol levels in rats. BM 170249 strongly induces the activity of key enzymes in the peroxisome fatty acid β-oxidation system (such as acyl-CoA oxidase AOX, multifunctional enzyme PH, and thiolase PT), but leads to decreased activity of catalase and uricase in peroxisome components. BM 170249 could be used in lipid-lowering studies .
    BM 170249
  • HY-14998
    Halofenate

    MK 185

    		 β-catenin PPAR Wnt Endocrinology
    Halofenate, structurally akin to clofibrate, was evaluated in hypertriglyceridemic patients over 6-week periods in a controlled, double-blind crossover trial. It effectively reduced serum triglycerides by 50%, with minimal impact on serum cholesterol levels. Additionally, it lowered serum uric acid by 30% and exhibited uricosuric effects independent of glomerular filtration rate. Halofenate was associated with a significant increase in plasma thyroxine (T4), accompanied by a decrease in protein-bound iodine and T4 by column. In vitro studies confirmed its ability to displace T4 from thyroid-binding proteins, suggesting a thyroxine-displacing effect, which could influence thyroid function in vivo .
    Halofenate
  • HY-186096
    LP-856866

    		ACSL Family GLP Receptor Metabolic Disease
    LP-856866 is an orally active ACSL5 inhibitor, with IC50 values of 8 nM and 4 nM against mouse and human ACSL5, respectively, and IC50 values of 6 nM and 17 nM against mouse and human ACSL1, respectively. LP-856866 induces delayed gastric emptying, promotes GLP-1 release, reduces food intake, decreases body weight and body fat mass, preserves lean body mass, improves glucose homeostasis, enhances insulin sensitivity, reduces hepatic lipid accumulation, and lowers serum triglyceride and total cholesterol levels. LP-856866 is applicable to research on diet-induced obesity .
    LP-856866

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: